BioSpace News Archive

Using a pocket-sized, portable DNA sequencer based on nanopore sequencing technology pioneered at UC Santa Cruz, the scientists sequenced a complete human genome, in fragments hundreds of times larger than usual, enabling new biological insights.

BofA Merrill Lynch, Cowen and Leerink Partners are acting as joint book-running managers for the offering.

Puma Biotech today announced that on January 16, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement stock option to purchase 90,000 shares of Puma common stock to Douglas Hunt in connection with Mr. Hunt’s commencement of employment with the Company as its Senior Vice President of Regulatory Affairs.

Ocular Therapeutix today announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share.

The drug met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants.

The trial has been approved to enroll up to 343 subjects at up to 40 U.S. centers.

In a study of 34 older patients, researchers at Indiana University School of Medicine found that those who scored less well on a standard test of smell were more likely to have more tau protein concentrations in their brains, particularly in regions associated with the sense of smell.

Amgen today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the close of the U.S. financial markets.

Hologic announced today that holders of the 2.00% Convertible Senior Notes due 2042 issued March 5, 2012 have the right to surrender their notes for repurchase by the Company.

The presentation is scheduled for 2:15 pm Eastern Time on February 1, 2018.